Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 3,978 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
Interventions: Eculizumab; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Los Angeles, California • Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Survivorship, Cognitive Dysfunction, Pain, Depression, Anxiety, Fatigue, Sleep Disturbance
Interventions: Cognitive Dysfunction; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Erectile Dysfunction
Interventions: Low-intensity acoustic shockwave therapy; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Great Neck, New York • Lake Success, New York

Conditions: Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
Interventions: Regadenoson, Gadolinium, Cardiac MRI; Drug · Procedure
Lead sponsor: Paul Kim; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Brain Diseases, Epilepsy, Memory Disorders, Traumatic Brain Injury, Cognitive Impairment, Post Traumatic Stress Disorder
Interventions: Intracranial Stimulation; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Depression in Old Age
Interventions: On-site AE, At-home AE, Social Engagement (SE); Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Peripheral Artery Disease (PAD)
Interventions: Not listed
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Arlington, Texas

Conditions: Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Enrollment: 23 participants
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cognition Disorders
Interventions: Cognitive Strategy Training, Placebo comparison group; Behavioral · Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: San Diego, California • Boise, Idaho • Portland, Oregon + 1 more

Conditions: Aging, Dementia, Cognitive Decline
Interventions: utmbHealthyBrain Smartphone App; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 50 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Atrial Fibrillation
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 16,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Right Ventricular Dysfunction
Interventions: 3D TEE RVEF; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer's Dementia
Interventions: Resonator; Device
Lead sponsor: pico-tesla Magnetic Therapies, LLC; Industry
Eligibility: 55 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Blepharitis
Interventions: KPI-121, Vehicle; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Regular Insulin, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 55 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cardiomyopathy, Renal Impairment
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Endonasal Surgery, Endoscopic Sinus Surgery, Olfactory Dysfunction
Interventions: CONVIVO system, Fluorescein injection, USP 10%; Device · Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cerebral Palsy (CP), Stroke, Spinal Cord Injury, Traumatic Brain Injury, Charcot Marie Tooth Disease (CMT), Spina Bifida
Interventions: Participate in high intensity exercise of at least 20 minutes in 60 minutes session of RPE greater than 6.; Behavioral
Lead sponsor: University of Hartford; Other
Eligibility: 8 Years to 99 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: West Hartford, Connecticut

Conditions: Alzheimer Disease, Alzheimer Dementia
Interventions: GENUS device (Active Settings), GENUS device (Sham Settings); Device
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 50 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Hypertension
Interventions: Effects of dark chocolate; Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Endometriosis
Interventions: 75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo capsule to match Add-back capsule; Drug
Lead sponsor: Kissei Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Dothan, Alabama • Homestead, Florida • Tampa, Florida + 5 more

Conditions: Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions: Low-added sugar, high-fat diet, High-added sugar, high-fat CF diet; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Physical Functional Impairment, Cognitive Impairment
Interventions: Artmaking and exergaming; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cognitive Decline
Interventions: 540,000 IU vitamin D3, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more

Search by objective public record fields.

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

Biobehavioral Correlates of Cancer-related Cognitive Dysfunction and Its Co-occurring Symptoms

Changes in Penile Firmness With Low-Intensity Shockwave Therapy (LiST)

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

Amygdala Memory Enhancement

Fitness for Brain Optimization for Late-Life Depression

Using Near-Infrared Light to Better Understand Peripheral Artery Disease

Growth Hormone Dynamics and Cardiac Steatosis in HIV

Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder

Feasibility of A Smartphone Application Intervention in Community Settings: A Pretest-Posttest Pilot Study

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

TEE 3D RV Assessment for SAVR, Mini AVR, and TAVR

Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

In Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy

High Intensity Exercise and Improving Physical Activity Among People With Neurologic Dysfunction

Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease

Effects of Dark Chocolate on Insulin Sensitivity in People With High Blood Pressure

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

FEED-Cystic Fibrosis (FEED-CF)

Community Recreation to Enhance Function in Aging

Vitamin D to Improve Outcomes by Leveraging Early Treatment: Long-term Brain Outcomes in Vitamin D Deficient Patients